The CMT Research Foundation (CMTRF), a non-profit focused solely on delivering treatments and cures for Charcot-Marie-Tooth disease* is pleased to announce that Maximiliano Barrientos has joined its Board of Directors. Mr. Barrientos is a Co-founder, Investor and CFO of EntreConsultas.AI, a start-up in artificial intelligence providing biometric authentication services to fintech and insurance companies.
“We invited Mr. Barrientos to join the Board because his experience, knowledge and relationships can help the CMT Research Foundation develop innovative funding models that will enable us to leverage current trends in disease-focused nonprofit funding,” says Patrick Livney, CMTRF’s Co-founder and Chairman of the Board of Directors. “CMTRF’s model ensures that if the projects in which we invest come to market and generate a profit, we share in those proceeds as a way to fund additional research. Mr. Barrientos will help take us to the next level of best-in-class funding.”
“I am pleased and honored to join the CMT Research Foundation Board. CMTRF has made remarkable progress in just three and a half years,” says Mr. Barrientos. “As someone who lives with CMT, I understand the complexity – and urgency – of finding a cure. So, I share CMTRF’s vision and singular mission. I will help in every way possible to accelerate CMTRF’s strong momentum.”
Before EntreConsultas.AI, Mr. Barrientos spent 11 years with TE Connectivity based in Berwyn, PA (a $15 billion Swiss technology company that designs and manufactures connectors and sensors), serving in financial positions of increasing scope and responsibility. Before that, he was with Bunge Limited (a $50 billion food and agribusiness company headquartered in White Plains, NY) as Strategic Planning Associate. Mr. Barrientos started his career with General Motors as a Finance Analyst based in Buenos Aires. He holds an MBA from Wharton and a degree in Business Administration/CPA from Argentina’s Universidad Austral.
The CMT Research Foundation (CMTRF) is focused solely on delivering treatments and cures for CMT. Founded by two patients who are driven to expedite drug delivery to people who live with CMT globally, the organization funds research for drug development. The 501(c)(3) federal tax-exempt organization is supported by personal and corporate financial gifts.
*Charcot-Marie-Tooth encompasses a group of inherited, chronic peripheral neuropathies that result in nerve degradation. CMT patients suffer from progressive muscle atrophy of legs and arms causing walking, running and balance problems and abnormal hand and foot functioning. Some forms of the disease also affect the nerves responsible for sight, hearing, breathing and brain function. CMT affects one in 2,500 people (about the same prevalence as multiple sclerosis) including 150,000 Americans and nearly 3 million people around the world. At the moment, there is no treatment or cure for CMT.
